Noor Ul Ain Rehman
Sun, May 10, 2026 astatine 6:13 PM CDT 2 min read
Enliven Therapeutics, Inc. (NASDAQ:ELVN) besides received a standing update from Clear Street connected April 27. The steadfast lifted the terms people connected the banal to $55 from $36, maintaining a Buy standing connected the shares. The steadfast stated that it near meetings with absorption with accrued condemnation successful ELVN-001 arsenic a differentiated ATP-site binder for BCR-ABL1. For further reference, Enliven Therapeutics, Inc. (NASDAQ:ELVN) reported successful fiscal Q4 and afloat twelvemonth 2025 net that it has a beardown equilibrium with $463 cardinal successful cash, currency equivalents, and marketable securities, which is anticipated to supply currency runway into the archetypal fractional of 2029.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is simply a clinical-stage biopharmaceutical institution with a absorption connected the find and improvement of small-molecule therapeutics. The company’s pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.
While we admit the imaginable of ELVN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

5 days ago
8





English (CA) ·
English (US) ·
Spanish (MX) ·